Quintiles deepens its Latin American ties with Argentine partnership

Quintiles ($Q) is further entrenching itself in Latin America, striking a deep-rooted alliance with a research site in Buenos Aires to widen its global network of trusted partners.

The CRO giant has added Hospital Italiano to its Prime Site program, a worldwide network of research facilities with which Quintiles has a collaborative relationship that goes beyond the standard interaction between sites and sponsors. Quintiles works with its Prime Sites to build out their infrastructure, improve patient recruitment and design better trials, the company said, and the program is meant to allow for rapid enrollment and study startup. By stepping in and improving global sites, Quintiles can better ensure things go according to plan in the make-or-break early stages of a clinical trial.

Hospital Italiano is Quintiles first Prime Site in Latin America, building upon a relationship that has paired the two institutions on more than 60 trials in 12 therapeutic areas, the company said.

"Strong relationships with sites is only the beginning," Quintiles Senior Vice President Jeanne Hecht said in a statement. "Together, these solutions and services enable patients to better manage their personal health, including opportunities to participate in clinical research, observational studies and disease management programs."

Meanwhile, Quintiles is looking forward to another record revenue year, expecting 2015 sales to grow between 7.5% and 9% over the prior year and forecasting earnings growth of 12% to 16%. The CRO pulled in $4.2 billion in revenue in 2014, clocking 9.4% growth.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.